Pliant Therapeutics vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 53)
Pliant Therapeutics logo

Pliant Therapeutics

ChallengerBioTech

Fibrotic Disease

Pliant Therapeutics is a clinical-stage biotech (Nasdaq: PLRX) developing integrin inhibitors for fibrotic diseases, with lead program bexotegrast in Phase 2b/3 trials for idiopathic pulmonary fibrosis.

AI VisibilityBeta
Overall Score
C53
Category Rank
#51 of 198
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
50
Perplexity
57
Gemini
57

About

Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH/MASH). Integrins are cell surface receptors that activate TGF-β, the master regulator of fibrosis — blocking specific integrin subtypes (αvβ6, αvβ1) can halt or reverse fibrosis progression without broadly suppressing immunity.

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

53
Overall Score
74
#51
Category Rank
#11
81
AI Consensus
68
stable
Trend
stable
50
ChatGPT
71
57
Perplexity
68
57
Gemini
80
57
Claude
77
56
Grok
69

Key Details

Category
Fibrotic Disease
AI-Enabled Precision Medicine
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Pliant Therapeutics
Fibrotic Disease

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.